Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer

• Published in: Hinyokika kiyo. Acta urologica Japonica Vol. 32; no. 11; p. 1763
• Main Authors: Nishio, S, Kishimoto, T, Maekawa, M, Kawakita, J, Hayahara, N, Yuki, K, Morikawa, Y, Yasumoto, R, Kato, Y, Funai, K
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.11.1986
• Subjects: Drug Evaluation; Estramustine - administration & dosage; Estramustine - adverse effects; Estramustine - therapeutic use; Humans; Male; Nitrogen Mustard Compounds - therapeutic use; Prostatic Neoplasms - drug therapy
• ISSN: 0018-1994

Estramustine phosphate disodium (Estracyt) was used in the treatment of 40 patients with prostatic carcinoma. Of these 20 patients 18 were treated with Estracyt as primary treatment and 22 had been treated with diethyl stilbestrol dephosphate and/or bilateral orchiectomy for more than 4 months before the Estracyt treatment. The drug was given orally in a dose of 560 mg/day in 2 divided oral doses. The clinical evaluation was done after 3 months treatment. The response in subjective symptoms and objective signs were documented and evaluated according to 5 criteria. In this study, Estracyt showed 80% improvement of dysuria, 60% of nykturia, 35% of pain and 55% of general condition. In objective signs, it showed 52.5% improvement of size of the prostate, 42.5% of consistency and 70% of residual urine. It would be emphasized that Estracyt had almost equal efficacy in both the primary treatment group and secondary treatment group. As side effects of this drug, gynecomastia, gastro-intestinal disturbance, angina pectoris like chest pain were observed.